Yokota, S., Nozawa, T., Kanetaka, T., Yamazaki, K., Sato, T., Sakurai, N., & Kikuchi, M. (2013). PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan. BioMed Central.
Citação norma ChicagoYokota, S., T. Nozawa, T. Kanetaka, K. Yamazaki, T. Sato, N. Sakurai, and M. Kikuchi. PReS-FINAL-2166: Long-term Safety and Effectiveness of Anti-interleukin-6 Receptor Monoclonal Antibody, Tocilizumab, in Patients With Systemic Juvenile Idiopathic Arthritis in Japan. BioMed Central, 2013.
Citação norma MLAYokota, S., et al. PReS-FINAL-2166: Long-term Safety and Effectiveness of Anti-interleukin-6 Receptor Monoclonal Antibody, Tocilizumab, in Patients With Systemic Juvenile Idiopathic Arthritis in Japan. BioMed Central, 2013.